GfK Bridgehead is a global market access consultancy, focusing on helping companies achieve the optimal market value for their innovations. Bridgehead has developed a core expertise in the diagnostics and personalized medicine space, working closely with both diagnostic and pharmaceutical manufacturers to realize the promise of this rapidly developing area.
Bridgehead’s team has in-depth experience evaluating personalized medicine technologies to help companies bring them to market. Recently, Bridgehead has conducted numerous projects in the personalized medicine space in the US and Europe covering topics ranging from regulatory approval pathways, pricing considerations, health technology assessments, risk-sharing and evidence development requirements. Bridgehead has a core expertise in the diagnostic space, fielding a team with over fifteen years of experience in reviewing market access issues specific to the diagnostic sector. Members of the Bridgehead team participate in several organizations specifically focused on the global pricing and reimbursement nuances of Diagnostics products. For example, Susan Garfield sits on ISPOR’s Diagnostic Health Technology Assessment Special Interest Group (SIG) and has just completed development of ISPOR’s US Diagnostic Payment Roadmap.
Overall, Bridgehead’s exposure to hundreds of innovative technologies a year with many in the personalized medicine space, gives us a broad-based perspective on the market access considerations related to the evolving personalized medicine landscape.